Research Article
Sequential Measurements of Pentraxin 3 Serum Levels in Patients with Ventilator-Associated Pneumonia: A Nested Case-Control Study
Table 1
Baseline characteristics of the study patients.
| | Characteristics | Confirmed VAP () | Clinically suspected VAP () | Without VAP suspicion () | value |
| | Antimicrobial use during respiratory sample collection | 12 | 11 | 17 | 0.36 | | Quantitative culture negative | 0 | 27 | 32 | 0.01 | | Quantitative culture <1 × 105 cfu/mL | 0 | 4 | 0 | 0.01 | | Quantitative culture ≥1 × 105 cfu/mL | 28 | 0 | 0 | 0.01 | | CPIS, median (25–75%) | 7 (3–7) | 3 (1–5) | 2 (1–3.7) | <0.01 |
| | Characteristics | VAP, (%) | Non-VAP controls, (%) | value | | Age (years), mean ± SD | 54.2 ± 3.6 | 59.3 ± 2.2 | 0.88 | | Sex: female, n (%) | 6 (21.4) | 9 (29) | 0.56 | | Days in ICU, median (25–75%) | 28 (12.5–42) | 9 (7–16.5) | 0.001 | | Duration of MV (days), median (25–75%) | 28 (11.5–36) | 9 (6–16.5) | 0.001 | | Admission diagnosis | | | | | Emergency surgery | 9 (32.1) | 15 (24.6) | 0.73 | | Elective surgery | 6 (21.4) | 20 (32.8) | 0.73 | | Trauma | 6 (21.4) | 6 (9.8) | 0.73 | | Medical | 7 (25) | 20 (32.8) | 0.73 | | APACHE II score, median (25–75%) | 21 (15–24) | 20 (15–23.5) | 0.50 | | SOFA score, median (25–75%) | 6 (4–10) | 8 (6–11) | 0.07 | | CPIS, median (25–75%) | 6 (3–7) | 2 (1–5) | 0.001 | | Crude mortality, n (%) | 15 (53.6) | 40 (65.6) | 0.34 | | 28-day mortality, n (%) | 13 (46.4) | 24 (40) | 0.25 | | D0 pentraxin 3 (ng/mL) | 0.32 (0.03–1.2) | 0.06 (0.02–0.39) | 0.07 | | D0 procalcitonin (ng/mL) | 1.0 (0.32–2.7) | 0.34 (0.18–4.37) | 0.32 | | D0 CRP (µmol/L) | 70 (38.7–149.7) | 100 (47–204) | 0.19 |
|
|
ICU: intensive care unit; MV: mechanical ventilation; APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CPIS: Clinical Pulmonary Infection Score.
|
